• Molecular NameNitazoxanide
  • Synonym2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide; 2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide; Nitazoxanid; Nitazoxanida [INN-Spanish]; nitazoxanide; Nitazoxanidum [INN-Latin]; NTZ; Tizoxanide Glucuronide
  • Weight307.286
  • Drugbank_IDDB00507
  • ACS_NO55981-09-4
  • Show 3D model
  • LogP (experiment)2.565
  • LogP (predicted, AB/LogP v2.0)2.27
  • pka6.18
  • LogD (pH=7, predicted)1.31
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-2.92
  • LogSw (predicted, AB/LogsW2.0)0.11
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors1
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds5
  • TPSA145.36
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability70.0
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFollowing oral administration, it is rapidly hydrolyzed to its active metabolite, tizoxanide
  • Half lifeN/A
  • ExcretionRenal, biliary and fecal; approximately 67% of the oral dose of nitazoxanide is excreted in the feces and 33% in the urine.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse reactions include headache, abdominal pain, diarrhea, nausea, vomiting.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A